Kingworld Medicines Group Limited (01110.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.0x

Market Cap

HKD 261.09M

MomentumView details →

1D Return

+3.70%

YTD Return

−19.23%

RSI (14)

45.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

4.0x

Market Cap

HKD 261.09M

RSI (14)

45.2

MomentumView details →

1D Return

+3.70%

YTD Return

−19.23%

ProfitabilityView details →

Gross Margin

27.49%

Net Margin

0.98%

EBITDA Margin

7.64%

ROE (TTM)

2.83%

ROA (TTM)

1.30%

Asset Turnover

1.26x

GrowthView details →

Revenue YoY

−19.55%

EPS YoY

−74.56%

FCF YoY

−47.05%

Revenue CAGR 3Y

−1.42%

EPS CAGR 3Y

−20.00%

EBITDA YoY

−36.43%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.73x

Current Ratio

1.05x

Quick Ratio

0.78x

Div Yield

—

Div Rate

—

Div Growth 1Y

−6.21%

Financials snapshotView financials →

Revenue (TTM)

1.72B

Net Income (TTM)

16.90M

Op. CF (TTM)

57.02M

Latest newsMore news →

Kingworld Medicines Group announced its interim results for the six months ended June 30, 2026, with revenue of 275 million RMB, down 32% year-on-year, net loss narrowing from 5.41 million RMB in the prior-year period to 5.22 million RMB, loss per share of 0.9 cents, and no dividend.8d ago

Similar companies

High Tide Inc.HITI Vicore Pharma Holding ABVCRE Tycoon Group Holdings Limited03390.HK Clinuvel Pharmaceuticals Ltd.CUVL Satellos Bioscience Inc. Common StockMSLE LifeMD, Inc.LFMD Find similar companies →

Latest newsMore news →

Kingworld Medicines Group announced its interim results for the six months ended June 30, 2026, with revenue of 275 million RMB, down 32% year-on-year, net loss narrowing from 5.41 million RMB in the prior-year period to 5.22 million RMB, loss per share of 0.9 cents, and no dividend.8d ago